CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Ceribell, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$26.00+0.96 (+3.83%)

Close on Oct 19, 2026

Market cap: $988.83M
P/E (TTM): –
Dividend yield: –

Dividends

Ceribell has not reported a dividend

No dividend per share appears in Ceribell's annual filings since fiscal 2022.

Where these numbers come from

Parsed from the XBRL in Ceribell's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CBLL.

Revenue growth31.7% · median 15.3%

Gross margin88.9% · median 51.4%

Operating margin-68.6% · median -15.3%

Net margin-64.7% · median -19.3%

Company	Revenue	Growth
OM	$117.80M	-1.3%
CBLL	$101.96M	+31.7%
NPCE	$98.84M	+16.9%
ELMD	$73.78M	+15.3%
IRIX	$51.57M	+3.7%
HYPR	$16.54M	+53.2%

Company

Next earnings (est.): Nov 3, 2026, after close
Exchange: Nasdaq
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 327
Held by institutions: 79.5%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1861107

Advertisement
300 × 250